MRI tracing non-invasive TiO 2 -based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer ∗

作者：Pu Yuan, Dongkui Song · 发表于：Nanotechnology · 年份：2018 · DOI：10.1088/1361-6528/aaa92a · 被引用次数：36 · 研究领域：Nanoplatforms for cancer theranostics、Nanoparticle-Based Drug Delivery、Photoacoustic and Ultrasonic Imaging

Abstract To reduce the side effects of chemotherapy and achieve effective and safe therapy for prostate cancer, herein a simple but multi-functional TiO 2 :Gd@DOX/FA system activated by ultrasound was developed for the MRI-guided multi-mechanism therapy of prostate cancer. TiO 2 nanoparticles served as a sonosensitizer as well as a nanocarrier with the pH-responsive release of DOX. The doping of Gd was not only able to endow the TiO 2 with magnetic resonance imaging (MRI) ability, but also further improve the sonodynamic ability of the TiO 2 . The characterization of the as-prepared TiO 2 :Gd@DOX/FA showed sensitive pH-responsive drug release, high reactive oxygen species (ROS) production, T 1 -MRI contrast performance and excellent biocompatibility. The cytotoxicity assay in vitro showed cell death up to 91.68% after 48 h incubation induced by the TiO 2 :Gd@DOX + ultrasound group. Meanwhile, in the in vivo synergistic therapy studies, the tumor sizes of all the nanomedicine groups were smaller than for the free DOX ( V : V 0 = 4.2). More importantly, the body showed nearly no weight loss. This safety was also confirmed by the H&E staining, biodistribution experiment and serum biochemistry results. Altogether, TiO 2 :Gd@DOX/FA significantly reduced the side effects of DOX, augmented the levels of ROS and achieved effective and safe therapy, indicating its potential for the multi-mechanism therapy of prostate cancer.